Have you tried to create a molecule with a Contract Research Organization (CRO) but it didn’t work? Are you searching an optimal and functional molecule to address a specific health issue? Is your company seeking quick and effective solutions for your drug discovery projects?
The Institute of Chemical Research of Catalonia (ICIQ-CERCA) aims to facilitate knowledge and technology transfer to the pharmaceutical industry. ICIQ has several units that works for many discovery drug phases, including analytical measures and discovery procedures.
The MedChem Unit is specialized in all non-regulatory preclinical drug discovery phases, making it a valuable partner for pharmaceutical companies in need of efficient and timely solutions for their drug development projects. From hit identification to final drug development, the unit offers comprehensive support throughout the entire process.
With nearly 20 years of expertise, the unit have highly qualified personnel in the medicinal chemistry field who bring innovation to every project. The team has large experience in a wide range of therapeutics areas. The unit has collaborated with over 90 companies on more than 600 projects related to unmet medical needs, including those concerning the central nervous system, anticancer, antibiotic, antiviral, anti-inflammatory and antimalaria substances.
Applying ICIQ’s state-of-the-art technologies, the MedChem Unit offers services related to the discovery of new biological active structures, the diversification of these chemical structures to improve their activity and properties, drug design and optimization of their properties, synthesis of small molecules, design and synthesis of new or alternative synthetic routes, and the computer assisted drug design to improve its efficiency.
Additionally, the team benefits from ICIQ’s know-how and the Core Facilities Area, including Characterization and Reaction Technologies, which provides them with the necessary state of the art scientific instrumentation to carry on the pharmaceutical projects.
MedChem acknowledges the support of the State Research Agency / Ministry of Science and Innovation under the “Severo Ochoa” Centres of Excellence Program (CEX2019-000925-S, MCIN/AEI/10.13039/501100011033, 2020-2024)
